Park, Joon Seok http://orcid.org/0000-0003-4001-6886
Gazzaniga, Francesca S.
Wu, Meng
Luthens, Amalia K. http://orcid.org/0000-0003-2179-712X
Gillis, Jacob
Zheng, Wen
LaFleur, Martin W.
Johnson, Sarah B. http://orcid.org/0000-0001-8936-0958
Morad, Golnaz http://orcid.org/0000-0002-9460-618X
Park, Elizabeth M.
Zhou, Yifan
Watowich, Stephanie S. http://orcid.org/0000-0003-1969-659X
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Freeman, Gordon J. http://orcid.org/0000-0002-7210-5616
Kasper, Dennis L. http://orcid.org/0000-0001-8808-5333
Sharpe, Arlene H. http://orcid.org/0000-0002-9736-2109
Article History
Received: 4 February 2022
Accepted: 28 March 2023
First Online: 3 May 2023
Change Date: 1 June 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-06237-8
Competing interests
: J.S.P., F.S.G., D.L.K. and A.H.S. are listed as inventors on US Utility application (17/311,587) covering identification of gut bacteria that promote an anti-tumour response to immunotherapy filed by President and Fellows of Harvard College. J.S.P., F.S.G., D.L.K. and A.H.S. are listed as inventors on US Utility application (17/473,083) covering methods and compositions for treating cancer or a tumour in a subject by administering to the subject a first agent that disrupts the interaction between PDL2/RGMb and a second agent that disrupts the interaction between PD-1/PD-L1 filed by President and Fellows of Harvard College. J.S.P., F.S.G., G.J.F., D.L.K. and A.H.S. are listed as inventors on PCT patent applications (PCT/US21/50674) covering methods of treating an individual that has failed an anti-PD-1/PD-L1 therapy filed by President and Fellows of Harvard College and Dana-Farber Cancer Institute. J.S.P., F.S.G., G.J.F., D.L.K. and A.H.S. are listed as inventors on PCT patent applications (PCT/US23/12139) covering methods and compositions for treating cancer or a tumour in a subject by administering to the subject T cells with reduced RGMb expression or activity and an immune checkpoint inhibitor such as a PD-1 or PD-Ll inhibitor filed by President and Fellows of Harvard College and Dana-Farber Cancer Institute. J.S.P., F.S.G., G.J.F., D.L.K. and A.H.S. are listed as inventors on provisional patent application covering PD-L2 modulated dendritic cell therapy filed by President and Fellows of Harvard College and Dana-Farber Cancer Institute. G.J.F. is listed as an inventor on US patent US11220545 on combination RGMb and PD-1 blockade for cancer immunotherapy assigned to Dana-Farber Cancer Institute. G.J.F. and A.H.S. have patents/pending royalties on the PD-1–PD-L1 pathway from Roche, Merck MSD, Bristol-Myers Squibb, Merck KGA, Boehringer-Ingelheim, AstraZeneca, Dako, Leica, Mayo Clinic, and Novartis as listed in Supplementary Table InternalRef removed. G.J.F. has served on advisory boards for Roche, Bristol-Myers-Squibb, Xios, Origimed, Triursus, iTeos, NextPoint, IgM, Jubilant, Trillium, GV20, IOME, and Geode. G.J.F. has equity in Nextpoint, Triursus, Xios, iTeos, IgM, Trillium, Invaria, GV20, and Geode. A.H.S. has patents/pending royalties on the PD-1 pathway from Roche and Novartis. A.H.S. is on advisory boards for Surface Oncology, SQZ Biotechnologies, Elpiscience, Selecta, Bicara and Monopteros, Bicara, Fibrogen, IOME and Alixia. She also is on scientific advisory boards for the Massachusetts General Cancer Center, Program in Cellular and Molecular Medicine at Boston Children’s Hospital, the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, GlaxoSmithKline, Janssen and Amgen. She is an academic editor for the <i>Journal of Experimental Medicine</i>. A.H.S. has received research funding from Novartis, Roche, UCB, Ipsen, Merck, AbbVie, Moderna, Vertex and Erasca unrelated to this project. D.L.K. is on a scientific advisory board of IOME. S.S.W. is on the advisory board for Asylia Therapeutics and reports compensation from Ridgeline Therapeutics. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb and serves as a consultant and advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Micronoma, and Biothera Pharmaceuticals, with stock options for Micronoma.